Allarity Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $13.89M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | – | $-0.21 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 1, 2026 | Before market open | $320.00K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | $-7.71 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-22.14 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 8, 2024 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 15, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 22, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 17, 2022 | After market close | – | – | – |
Press releases
Announcements Allarity Therapeutics filed with the SEC
PRESS RELEASE, DATED SEPTEMBER 30, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 28, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 15, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 11, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 30, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 30, 2026
Shareholder vote results · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 18, 2026
Other events · EX-99.1 to Form 8-K
Copyright © 2023 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Dual inhibition of PARP and WNT: A novel drug - biomarker combination in clinical trials Thomas Jensen, CEO
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 8, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE, DATED MAY 5, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 27, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 21, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MARCH 31, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MARCH 6, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 18, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 3, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 22, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 17, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 26, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 15, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 30, 2025.
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
Results of operations · EX-99.1 to Form 8-K
Allarity Therapeutics Presents Novel Drug Response Predictor — DRP ®— for Daratumumab in Multiple Myeloma at AACR 2025
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Reports Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Allarity Therapeutics Launches Comprehensive Effort to Combat
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Announces Final Settlement with
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Announces Board Authorization
Other events · EX-99.1 to Form 8-K
of Securities Class Action Lawsuit
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics to Begin Enrollment for
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Allarity Therapeutics to be Granted European Patent for DRP ® Companion Diagnostic for Stenoparib
Other events · EX-99.1 to Form 8-K
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K